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Prevention and Treatment of 
Iodine-Induced Thyrotoxicosis
Melinda Kolcsár and Zsolt Gáll
Abstract
Etiologies of thyrotoxicosis are diverse, one of them being caused by iodine-
induced hyperthyroidism. The clinical signs of the disease are the classical signs 
of any form of hyperthyroidism, but the treatment of the different forms presents 
particular aspects. This chapter reviews the risk factors for thyrotoxicosis following 
an excess iodine load, pointing out the major sources of iodine: supplementation 
programs, dietary intake, nutritional supplements, iodine-containing contrast 
medium, and amiodarone. Prevention of iodine-induced thyrotoxicosis is critical in 
geriatric patients who often have thyroid nodular disease, underlying heart condi-
tions, and therefore, hyperthyroidism may be more difficult to detect clinically. 
Treatment of iodine-induced thyrotoxicosis could be performed with thioamides or 
perchlorate prior to the administration of an iodine containing product (e.g., food, 
dietary supplements, and contrast media). On the other hand, amiodarone-induced 
thyrotoxicosis needs further attention and a close collaboration between cardiology 
and endocrinology to overcome complications, but individualization of the therapy 
should be undertaken. Based on the specific features of amiodarone-induced thyro-
toxicosis thioamides, perchlorate, high-dose glucocorticoids, or radioiodine therapy 
may be considered for an optimal therapeutic intervention.
Keywords: iodine deficiency, iodine supplementation, dietary iodine,  
iodine containing contrast media, amiodarone, thyrotoxicosis, thioamides, 
perchlorate, glucocorticoids
1. Introduction
Thyroxine (T4) and 3,5,3′-triiodothyronine (T3) are the two thyroid hormones, 
each of them containing two iodine atoms on their inner (tyrosine) ring. The 
difference between them is that T3 has only one iodine atom on its outer (phenyl) 
ring, whereas T4 has two. Synthesis of reasonable quantities of thyroid hormones 
requires adequate iodine intake to allow sufficient thyroidal uptake. The World 
Health Organization (WHO) recommendation for daily intake of iodine is 90 μg for 
infants and children up to 5 years, 120 μg for children 6–12 years, 150 μg for chil-
dren ≥12 years and adults, and 250 μg for pregnant and lactating women [1]. The 
worldwide variability of the dietary intake of iodine depends on the iodine content 
of the soil, water, and the dietary practice. After Iodine Global Network data [2], 
the iodine uptake in Romania in 2004 was considered adequate, the median urinary 
iodine content (MUIC, normal value ≥100 μg/L) being 102 μg/L in school-aged 
children, but in some geographic regions, such as mountainous villages of Mureș 
County, a mild iodine deficiency was detected [3]. The MUIC value (68 μg/L) in 
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pregnant women confirmed that iodine intake in this population of Romania is 
insufficient [2]. Administration of supplemental iodine to subjects with iodine defi-
ciency goiter can result in iodine-induced hyperthyroidism in nonpregnant persons 
[4], but iodine supplementation in mild and moderate iodine-deficient pregnant 
women lowers thyroid hormone level [5].
2. Risk factors for thyrotoxicosis following an iodine load
2.1 Normal adaptation to iodine intake
Thyroid hormone secretion is regulated by two mechanisms: a central hypo-
thalamic-pituitary and a local autoregulatory mechanism depending on the iodine 
content of the gland. The autoregulatory mechanism reduces the fluctuation of 
thyroid hormone secretion in the event of sudden changes in iodine supply. Iodine 
excess inhibits iodide accumulation, organogenesis, tyrosine binding, and thyroid 
hormone release. However, this inhibitory effect (Wolff-Chaikoff effect) lasts only 
10–14 days, followed by the so-called escape phenomenon [6].
Iodine is a micronutrient that is present in foods (e.g., seaweed, seafood, dairy- 
and grain products, eggs), added to processed foods as iodized salt, and available as 
a dietary supplement, but the iodine concentration of water and foods is highly vari-
able. Studies of iodine balance, based on the assumption that a healthy subject on an 
adequate diet maintains equilibrium between iodine intake and losses, have provided 
highly variable results, thus, cannot be used for setting daily reference values [7]. 
When iodine losses exceed intake (negative balance), deposits are progressively 
depleted resulting in biological signs and in clinical symptoms of deficiency. The 
physiological response to iodine deficiency is the preferential synthesis of T3 instead 
of T4. Long-term follow-up suggests that chronic iodine deficiency may lead to insuf-
ficient thyroid function (hypothyroidism) associated with a compensatory thyroid 
hypertrophy/hyperplasia with goiter (enlarged thyroid gland). Myxedema, observed 
with severe iodine deficiency, also results from hormone deficiency and is associ-
ated with reduced metabolic rate, weight gain, swollen face, edemas, hypothermia, 
and mental slowness. In euthyroid subjects, the plasma concentration of iodine 
(inorganic and organic iodine) ranged from 40 to 80 μg/L. Concentrations between 
80 and 250 μg/L are associated with hyperthyroidism, whereas concentrations above 
250 μg/L usually result from iodine overload with iodinated drugs [8, 9]. The thyroid 
gland, being highly flexible, is able to concentrate iodine up to 80-fold, and in most 
healthy adults, no clinical signs will appear at an iodine intake of up to 2 g/day [10]. 
However, if the adaptation to high iodine intake fails, various diseases occur. Chronic 
excessive iodine supply can also lead to goiter [11] and may accelerate the develop-
ment of subclinical thyroid disorders to overt hypothyroidism or hyperthyroidism, 
increase the incidence of autoimmune thyroiditis, and increase the risk of thyroid 
cancer [10, 12, 13]. Recently, high iodine intake (exceeding 160 μg daily) was sug-
gested as a risk factor for type 2 diabetes [14].
2.2 Iodine-induced thyrotoxicosis mechanisms
Iodine-induced hyperthyroidism (thyrotoxicosis) or Jod-Basedow effect is most 
frequently observed following iodine supplementation in individuals who had 
previously experienced severe iodine deficiency [15, 16]. A plausible explanation 
of this phenomenon can be the thyroid stimulating hormone (TSH) hyperstimula-
tion of the thyroid gland, which may occur as an adaptive response to the iodine-
deficient conditions and results in autonomous growth and function of thyrocyte 
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clusters. When iodine intake increases, these nodules may synthesize an excessive 
amount of thyroid hormones [10]. The mechanism consists of escape phenomenon 
when high doses of iodine are used for thyroid hormone synthesis, which can lead 
to severe thyrotoxicosis. The high iodine containing amiodarone and its metabolite 
N-desethylamiodarone (DEA) affects T cell function by increasing the number 
of both helper and cytotoxic T lymphocytes and induces destructive thyroiditis, 
resulting in transient thyrotoxicosis, as suggested by clinical, histological, and 
in vitro studies [17–19].
High levels of organic iodide (thyroid hormones) also reduce the accumulation 
of iodide ions in the thyroid gland inhibiting the TSH secretion.
The effects of iodine administration differ in patients with pre-existing thyroid 
pathology from those in healthy subjects and depend upon the underlying disease 
process.
3.  Major sources of increased iodine exposure: iodine supplementation, 
dietary iodine, iodine-containing contrast media, amiodarone, and 
the clinical forms of amiodarone-induced thyrotoxicosis
3.1 Iodine supplementation
The assessment of iodine deficiency can be accomplished by assessing the 
prevalence and severity of goiter, by testing the excretion of iodine in urine, and by 
determining hormonal levels (e.g., TSH, FT4). When used alone, neither of these 
are sufficiently sensitive and specific to measure iodine deficiency of a popula-
tion, but urinary iodine remains the index of choice in the monitoring of iodine 
supplementation programmes. The most successful method of intervention for 
iodine deficiency control is salt iodization, iodine being added to salt as potassium 
iodide (KI), potassium iodate (KIO3), or sodium iodide (NaI). Due to the high 
prevalence of hypertension and cardiovascular diseases, many countries proposed 
to promote the reduction of salt intake to 5 g/day (<2 g of sodium), so complemen-
tary measures are needed in order to tackle iodine deficiency [20]. But iodine also 
binds to fatty acids, so iodine oil can also be given orally or intravenously to severely 
iodine-deficient patients in the short term. Nascent iodine is like the precursor form 
of iodine, which converts into thyroid hormones. The human body can recognize 
and assimilate this form more easily than potassium salt. Lugol’s solution is a widely 
used commercial iodine source, which contains elemental iodine and potassium 
iodide also. If someone consumes high quantities of iodine-rich foods (e.g., marine 
food, kelp), the use of iodized salt or iodinated water may increase iodine levels 
above the safe upper level as recommended by WHO. Individuals, who consume 
large amounts of seaweed regularly, are also exposed to the risk of iodine-induced 
hyperthyroidism [21, 22]. Several reports are available describing diet-induced 
thyrotoxicosis in patients consuming seaweed-containing foods or beverages [23]. 
Risk factors for iodine induced hyperthyroidism include nontoxic or diffuse nodular 
goiter, latent Graves’ disease, and long-standing iodine deficiency [24].
3.2 Dietary supplements
Most dietary supplements, as well as food and water, contains iodine as salts: 
sodium iodide, sodium iodate, potassium iodide, and potassium iodate. Different 
solid dosage forms of potassium iodide are available, but around 20% is assimilated 
from inorganic forms of iodine into the body [25]. Iodine is also present in most 
multivitamin/mineral supplements. Some case reports described that previously 
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euthyroid patients taking nutritional supplements developed iodine-induced hyper-
thyroidism [26–28]. The iodine content of dietary supplements shows high variabil-
ity; some supplements may contain up to 160-fold of the recommended daily intake 
(Table 1). Short-term increase of basal and poststimulation TSH was described even 
in euthyroid patients administering dietary supplements with kelp [29, 30].
3.3 Iodine-containing contrast media
Iodinated contrast media (ICM) is given for computed tomography (CT), 
angiography, myelography, and arthrogram. The route of administration could be 
systemic as i.v, i.a., oral, rectal, and local. The pharmacokinetics of all currently 
available ICMs is similar. The half-life of ICM in normal renal function subjects 
is approximately 2 hours. Thus, approximately 20 hours are required for the total 
excretion of the administered ICM [31]. Referring to their iodine content and 
osmolarity, the contrast media are divided into ionic ICM with high osmolarity 
(1500–2000 mOsm/kg) or nonionic ICM with low and iso-osmolarity  
(600–1000 mOsm/kg). A list of iodinated contrast agents available in Romania and 
their molecular properties can be found in Table 2.
The safety profile of the systemic administered nonionic low- or iso-osmolar 
contrast currently in use is 5- to 10-fold better than the ionic high-osmolar agents 
[32, 33]. The ratio of iodine atoms to the number of contrast particles in low-
osmolar solution is higher than compared with high osmolar ICM and hence have 
a greater concentration of iodine than the high osmolar [32]. In both low and high 
osmolar ICM, the iodine content is far greater than the recommended daily allow-
ance. Patients generally are given 50 and 100 mL of contrast per CT scan; however, 
it is essential to know that not all CT scans require contrast media administration 
(see Table 3) [31, 33–35].
Higher doses of ICM may be required for invasive procedures such as cardiac 
catheterization. Typical doses for CT scans provide 2500–5000 μg of bioavailable 
free iodine and 15–37 g of total iodine [36]. Nonbioavailable iodine may be liberated 
to free iodide, particularly with increased half-times in the body (i.e., impaired kid-
ney function) [35, 36]. After ICM administration, iodine deposits remain elevated 
for up to 4–8 weeks in patients with healthy thyroid. The urinary iodine excretion 
increased by 300–400% from baseline to peak levels after 1.1 week and normalized 
by 5.2 weeks following ICM administration [37].
After exposure to the iodine-containing contrast agent, the most rapid (hours 
to days) effect of pharmacologic doses of iodine is the Wolff-Chaikoff effect. The 
Nutritional supplement Iodine content per 
serving (μg)
% RDA iodine per 
serving (%)
Natural Living Iodine Plus-2® 12500 8333
Terry Naturally® (Europharma) Tri-Iodine® 25000, 12500, 6250, 
3000
16667, 8333, 4167, 2000
Oradix StemDetox™ 5000 3333
Survival shield X-2, Detoxadine®  
(nascent iodine)
1950 1300
Dr. Mercola Iodine 1500, 500 1000, 333
Life Extension® sea iodine 1000 667
Table 1. 
Commercially available nutritional supplements with iodine content exceeding the daily intake recommended 
by WHO (RDA—recommended daily allowances).
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mechanism for this acute effect is partially explained by the generation of iodolac-
tones, iodoaldehydes, and/or iodolipids, which inhibit thyroid peroxidase activity, 
necessary for thyroid hormone synthesis [37]. The decrease of thyroglobulin 
proteolysis resulting in reduced thyroid hormone secretion also may be contribut-
ing to the ICM-induced Wolff-Chaikoff effect. The diminished serum T4 and T3 
concentrations temporarily increased the serum concentrations of TSH, in some 
cases above the normal range. The phenomenon is transient in euthyroid adult 
patients and does not typically determine permanent hypothyroidism [38].
Nonionic ICM Iodine content, 
mg/mL
Osmolarity
Watersoluble, nephrotropic X-ray contrast media
Iobitridol 300, 350 Low
Iodixanol 270, 320 Low
Iohexol 240, 300, 350 Low
Iomeprol 300, 350, 400 Low
Iopamidol 300, 370 Low
Iopromide 300, 370 Low
Ioversol 240, 300, 320, 350 Low
Non-watersoluble
Ethiodized oil 480
Table 2. 
The iodine content of nonionic iodinated contrast media (ICM) and their molecular properties.
CT type Contrast indicated Contrast not indicated
Head Neoplasm, meningitis, encephalitis, focal 
neurologic deficits, skull base disorders, 
orbital and vision disorders, pituitary imaging, 
complicated sinonasal disease, seizures, cerebral 
angiography
Head trauma, acute stroke, 
intracranial hemorrhage
Cervical Cervical mass or lymphadenopathy, suspected 
tumor or infection, abnormalities of cranial 
nerves X, XI, and XII, brachial plexopathy
Trauma unless arterial 
injury is a possibility or 
the mechanism of injury is 
penetrating
Cardiothoracic Heart and thoracic vessels, trauma, staging 
primary thoracic neoplasms
Coronary calcium scoring, 
pulmonary parenchymal 
evaluation lymph node 
evaluation
Abdominopelvic Virtually all other gastrointestinal, 
hepatopancreaticobiliary, genitourinary, 
gynecologic indications
Colonography, renal stone 
evaluation, extraparenchymal 
lymphoma
Musculoskeletal Evaluation of soft tissue masses and suspected 
septic arthritis or infected prostheses
Extremities and spine
CT angiography Evaluating the lumen of an artery, vein, or a 
pseudoaneurysm and to assess for end-organ 
ischemia outside the brain or lung to detect 
active bleeding
Monitoring a known 
aneurysm for growth or for 
detection of a hematoma
Table 3. 
Indications of contrast enhancement in CT imaging.
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ICM use could lead to thyroid dysfunction, namely to hypo- and hyperthyroid-
ism. Iodine excess-induced hypothyroidism appears when the thyroid fails to escape 
from the acute Wolff-Chaikoff effect. It occurs in patients with a wide variety of 
underlying thyroid abnormalities, including Hashimoto’s thyroiditis, previously 
treated Graves’ disease, history of thyroid lobectomy, postpartum lymphocytic 
thyroiditis, interferon therapy, or type 2 amiodarone-induced thyrotoxicosis  
[12, 39, 40]. Not only the previous thyroid disorder but also the age of the patients  
is a contributing factor in hypothyroidism development. A systematic review  
evidenced that hospitalized neonates, especially premature infants exposed to 
iodinated contrast media, are at increased risk for development of hypothyroid-
ism [41]. It could be hypothesized that hypothyroidism in this case to be partially 
secondary to an immature thyroid gland and an exaggerated Wolff-Chaikoff effect. 
Older age patients are also at high risk of developing hypothyroidism after ICM 
exposure, as reported in a study including the Asian population [42].
Patients with one exposure to ICM showed the highest risk of thyroid dysfunc-
tion compared with non-ICM exposure and a correlation was still found between 
the frequency of ICM exposure and the risk of hypothyroidism [42]. Conflicting 
data appear regarding to the time of onset of hypothyroidism after ICM administra-
tion: Rhee et al. [43] showed that the median time interval until the occurrence of 
hypothyroidism was 1 year, but Kornelius et al. [42] reported that hypothyroidism 
may develop 2.1 years after ICM exposure.
ICM-induced hyperthyroidism rarely occurs in individuals without prior 
thyroid dysfunction. Previously existent thyroid diseases, such as nodular goiter, 
Graves’ disease, and long-standing iodine deficiency followed by thyroid autonomy, 
were reported to be associated with a higher risk of hyperthyroidism after ICM 
exposure [4, 13, 24, 36, 42]. The mechanism of ICM-induced hyperthyroidism 
involves impairment of the acute Wolff-Chaikoff effect due to rapid iodine excess 
and influx into the thyroid gland. Excess iodine intake will result in transient or 
permanent hyperthyroidism [13, 24, 42]. Kornelius et al. [42] found in their study 
a 22% increased risk of hyperthyroidism after ICM administration. Older patients 
(between 20 and 60 years) presented a more than twofold increased risk of hyper-
thyroidism compared with younger patients (less than 20 years old). The number 
of ICM exposures did not increase the risk of hyperthyroidism. It could be hypoth-
esized that the “stunning effect” plays a certain role in hyperthyroidism, involving a 
diminished absorption of excess iodine in patients with repeated iodine exposure.
3.4 Amiodarone
3.4.1 Amiodarone pharmacology
Amiodarone is a class III antiarrhythmic agent, having short- and long-term 
actions on multiple molecular levels [44]. Its molecular structure resembles T3. 
However, amiodarone can alter thyroid function (inducing both hypo- and hyper-
thyroidism), which is due to amiodarone’s high iodine content and its direct toxic 
effect on the thyroid follicle cells. Amiodarone is a benzofuran derivative with great 
lipophilicity, which is extensively distributed in adipose tissue, cardiac and skeletal 
muscle, liver, lung, and the thyroid. During its liver metabolization, approximately 
6 mg of inorganic iodine per 200 mg of amiodarone ingested is released into the 
systemic circulation [45]. The average iodine content in Romanian diet is approxi-
mately 50–75 μg/day [3, 46, 47]. Thus, 6 mg of iodine markedly increases the 
daily iodine load. Amiodarone elimination from the body occurs with a half-life of 
approximately 55–100 days. The long half-life of both amiodarone and his active 
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metabolite, DEA, contributes to his toxicity. For a therapeutic effect, a plasma 
concentration between 0.5 and 2.5 μg/mL is required; however, serum levels do not 
correlate well with efficacy or with adverse effects [45, 48–50].
3.4.2 Amiodarone and the thyroid
The effects of amiodarone on thyroid function can be divided into those effects 
that are due to iodine and those effects that are intrinsic properties of the drug.
3.4.2.1 Effects due to iodine
After chronic amiodarone administration, the thyroid dysfunctions may occur 
in 5–22% of the patients. Risk factors for the development of thyroid disease include 
not only treatment duration and cumulative amiodarone dose but also age, gender, 
pre-existing thyroid pathology, and associated nonthyroid conditions [51–53]. 
The normal autoregulation process of thyroid prevents normal individuals from 
becoming hyperthyroid after exposure to the high iodine content substances. When 
intrathyroidal iodine concentrations reach a critically high level, iodine transport and 
thyroid hormone synthesis are transiently inhibited until intrathyroidal iodine stores 
return to physiological levels (see the Wolff-Chaikoff effect). Patients with underly-
ing thyroid pathology, however, have defects in autoregulation of iodine: for exam-
ple, in autoimmune thyroid disease exists a “fail to escape” from the Wolff-Chaikoff 
effect. The result is the development of goiter and hypothyroidism in Hashimoto’s 
disease. Patients with areas of autonomous function within a nodular goiter do 
not autoregulate iodine and the addition of more substrate may result in excessive 
thyroid hormone synthesis and thyrotoxicosis (see Iod-Basedow) [13, 54, 55].
3.4.2.2 Intrinsic drug effects
Amiodarone inhibits peripheral deiodinase (outer ring 5′-monodeiodination 
of T4), thus decreasing T3 production and increasing T4 level; reverse T3 (rT3) 
accumulates since it is not metabolized to T2 [4, 56, 57]; amiodarone and, particu-
larly, the metabolite DEA block T3-receptor binding to nuclear receptors [58] and 
decrease the expression of some thyroid hormone-related genes [59]; amiodarone 
may have a direct cytotoxic effect on thyroid follicular structures, which results 
in a destructive thyroiditis [60]. Martino et al. described marked distortion of 
thyroid follicle architecture, necrosis, apoptosis, inclusion bodies, lipofuscino-
genesis, markedly dilated endoplasmic reticulum, and macrophage infiltration 
after amiodarone [19]. The role of the pre-existing autoimmune process is widely 
debated, due to the conflicting results of the retrospective study data [17, 18, 55]. 
Even if amiodarone does not induce de novo autoimmune thyroid disease, by the 
direct cytotoxic effect, it may cause the release of pre-existing autoantibodies and 
thus worsen destructive thyroiditis. In a study [61], it was described that in women 
the prolonged amiodarone treatment (for over 2 years) increased the antithyroid 
peroxidase titer.
3.4.3 Risk of thyrotoxicosis after amiodarone administration
Predisposing factors for amiodarone-induced thyrotoxicosis include environ-
mental factors such as dietary iodine (deficiency), as well as intrinsic factors such 
as pre-existing thyroid pathology. Depending on these factors, a great variability 
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exists regarding the incidence of amiodarone-induced thyroid dysfunction ranges 
(5–22%) [51, 52, 62, 63].
Dietary iodine intake affects an individual’s risk of amiodarone-induced 
thyroid dysfunction: in iodine-deficient areas, amiodarone-induced thyrotoxi-
cosis (AIT) appears to be more common than hypothyroidism [64], whereas in 
iodine-sufficient areas, amiodarone-induced hypothyroidism is more common 
than hyperthyroidism [19]. The incidence of reported AIT in different studies 
varies but remains within the range of 5–10% in most studies [51, 52, 63]. As was 
reported in a previous study from the UK, AIT appears more frequently in men 
than in women [65], but the time of onset of AIT is unpredictable. It can occur 
at almost any time throughout the course of amiodarone treatment and last for 
as long as 6–9 months after treatment withdrawal, almost certainly because of 
the drug’s long half-life and associated iodine load [66]. One study illustrates 
the importance of the underlying thyroid status near the dietary iodine intake in 
relation to the risk of developing amiodarone-induced thyroid dysfunction. In 
Worcester, Massachusetts, an area with iodine sufficiency and a high prevalence 
of autoimmune thyroid disease, amiodarone was associated with a 2% rate of 
hyperthyroidism. In contrast, in Pisa, Italy, an area of borderline iodine intake and 
a high prevalence of nodular goiter, amiodarone was associated with 9.6% rate of 
hyperthyroidism [67].
The clinical effects of amiodarone on thyroid function in any individual are 
dependent upon the underlying status of that individual’s thyroid gland. In euthy-
roid individuals receiving amiodarone, acute changes in thyroid function tests 
include [68, 69]:
• Serum total T4 and free T4 concentrations rise by 20–40% during the first 
month of therapy.
• Serum T3 concentrations decrease by up to 30% within the first few weeks of 
therapy.
• Serum rT3 concentrations increase by 20% soon after the initiation of therapy.
• Serum TSH concentration usually rises slightly after the initiation of  
treatment and may exceed the upper limit of normal.
After 3–6 months of therapy, a steady state is reached in most patients who were 
euthyroid at baseline:
• Serum TSH concentration normalizes.
• Serum total T4, free T4, and rT3 concentrations remain slightly elevated or in 
the upper normal range.
• Serum T3 concentrations remain in the low normal range.
Amiodarone may also cause destructive thyroiditis with transient thyrotoxicosis 
followed by hypothyroidism in patients without underlying thyroid disease [60].
Abnormal thyroid process: in patients with underlying multinodular goiter or 
latent Graves’ disease, hyperthyroidism (increased synthesis of T4 and T3) may 
occur. The excess iodine from the amiodarone provides increased substrate, result-
ing in enhanced thyroid hormone production.
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3.4.4 Clinical forms of amiodarone-induced hyperthyroidism
Three types of AIT can be distinguished. In type 1 AIT, thyroid hormone syn-
thesis is increased, whereas in type 2 there is an excess release of T4 and T3 from the 
preformed thyroid hormones, due to destructive thyroiditis. Type 3 AIT is a mixed 
form, existing an overlapping condition between type 1 and type 2 AIT. These types 
differ in their pathogenesis, clinical or paraclinical signs, and management [63].
The risk of either type increases with higher cumulative doses or reintroduction 
of amiodarone [53, 70].
The distribution of AIT by type (1 or 2) varies by geographical region. This 
is thought to be primarily due to differences in dietary iodine intake. In iodine-
deficient regions, as some geographical zones were in Romania before universal 
salt iodization [3], AIT occurs in approximately 10–12% of patients with type 1 AIT 
usually predominating [64, 67]. However, the distribution of cases by type may 
be changing, as illustrated in a report of 215 consecutive patients with AIT seen at 
a single institution in Italy over 26 years [71]. In 1980 compared with 2006, 2 of 6 
(40%) versus 12 of 14 (86%) of new AIT cases were type 2. Possible explanations 
for this observation include improved dietary iodine intake in the region and the 
avoidance of amiodarone use in case of previously diagnosed thyroid disease. Our 
unpublished data from a study conducted in a single institute (Endocrinology 
Clinic, Târgu Mureș, Romania) in two different periods, which included 5 years, 
similarly show a moderate increase of type 2 AIT after the introduction of universal 
salt iodization (governmental decision no. 586/5 June 2002; see Table 4).
Clinical signs of AIT are classical thyrotoxicosis symptoms such as unexplained 
weight loss, proximal myopathy, restlessness, heat intolerance, low-grade fever, or 
exacerbation of tachyarrhythmia, heart failure, or angina pectoris; however, the 
adrenergic manifestations of amiodarone-induced hyperthyroidism are often masked 
because its distinct antiadrenergic properties and impairment of conversion of T4 to T3 
[68, 72]. Patients with amiodarone-induced hyperthyroidism have a threefold higher 
rate of major adverse cardiovascular events (mostly ventricular arrhythmias) com-
pared with euthyroid controls [73]. The presence of severe left ventricular dysfunction, 
especially in older patients with AIT, may be associated with increased mortality [74].
Differentiating the two types of AIT is critical since therapy differs. However, 
the distinction may be difficult using clinical criteria, partly because some patients 
may have a mixture of both mechanisms, presenting the type 3 (type 1 + type 2) 
AIT. Thyroid function tests (TSH, T4 and T3 plasma levels) do not help to distin-
guish type 1 AIT (hyperthyroidism) from type 2 AIT (transient thyrotoxicosis).
Type 1 AIT appears usually early after amiodarone introduction (3–20 months 
after exposure) [19, 66, 71]. It is characterized by hyperfunctional thyroid tissue with 
elevated blood flow on color Doppler [75, 76]. Furthermore, the enlarged or nodular 
thyroid tissue fixes either on 24-hour 123I-scan or on 99 mTc-SestaMIBI radio isotope 
scan despite the daily ingestion of 6 mg or more bioavailable iodine [77, 78].
Study 
period
Type 1 AIT/total patients Type 2 AIT/total patients Type 3 AIT/total patients
1994–1998 4/7 (57%) 1/7 (14%) 2/7 (29%)
2001–2005 17/38 (45%) 9/38(24%) 12/38 (31%)
Table 4. 
Distribution of AIT types in patients of the Endocrinology Clinic, Târgu Mureș, Romania, in two study periods 
(1994–1998 and 2001–2005).
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Type 2 AIT is a destructive thyroiditis which onset time is after 20–30 months 
of amiodarone introduction. It appears in patients with apparently normal thyroid 
morphology and is due to the massive release of thyroid hormones. The mechanism 
is similar to that of subacute thyroiditis, but the thyrotoxicosis is usually less severe 
and could spontaneously resolve in some cases [79]. The features of the two types of 
AIT are presented in Table 5.
However, interpretations of color flow Doppler sonogram in amiodarone-asso-
ciated hyperthyroidism require an experienced sonographer, and other markers for 
differential diagnosis were also sought. In two studies, serum interleukin-6 concen-
trations were higher in patients with type 2 AIT [80, 81]. In a third study, interleu-
kin-6 concentrations were not useful for distinguishing type 1 from type 2 AIT [76].
4. Prevention and treatment of iodine-induced thyrotoxicosis
Preventing therapy for iodine-induced hyperthyroidism is not generally recom-
mended. However, older patients with known multinodular goiter and/or subclini-
cal hyperthyroidism should be told of the risk for iodine-induced hyperthyroidism, 
and alternatives to contrast-enhanced CT scanning should be considered when 
appropriate (e.g., noncontrast CT, magnetic resonance imaging). Iodine-induced 
hyperthyroidism is particularly important in geriatric patients for several reasons: 
(1) the prevalence of thyroid nodular disease is higher in older patients than in 
younger patients, (2) the hyperthyroidism may be more difficult to detect clini-
cally, (3) apathetic hyperthyroidism often being present, and (4) older adults more 
often have underlying heart disease [21]. In high-risk patients (older, history of 
multinodular goiter with autonomy), treatment with a thioamide or perchlorate 
prior to the administration of an iodine load may blunt or prevent the induction of 
hyperthyroidism [82, 83]. However, there are insufficient randomized trial data 
to support the use of thioamides or perchlorate. Routine measurement of thyroid 
function tests (TSH, and if low, free T4 and T3) in older patients after exposure to 
iodinated radiographic contrast agents is favored by some experts, particularly since 
the symptoms of hyperthyroidism in older adults may be atypical [84–86].
Iodine-induced hyperthyroidism (iodine content supplements and dietary 
nutrients, ICM, type 1 AIT) is usually self-limited (lasting 1–18 months) if the 
source of iodine is discontinued. The American Thyroid Association (ATA) [87] and 
European Thyroid Association (ETA) recommendations [40] as initial therapy for 
patients with iodine-induced hyperthyroidism are discontinuation of iodine (except 
for amiodarone, which could be continued in type 2 AIT), avoidance of further 
exposure, and administration of a beta-adrenergic antagonist drug (assuming there 
Type 1 AIT Type 2 AIT
Pre-existing thyroid disease Yes No
Pathophysiology Iodine overload Destruction/inflammation
Ultrasound findings Goiter/nodule(s) Normal
Color flow Doppler Increased or 
vascularity
Reduced or absent vascularity
Radio iodine uptake (I123-Scan)/
SestaMIBI-Scan
Normal or increased Absent
Table 5. 
Characteristics of type 1 and type 2 amiodarone-induced thyrotoxicosis (AIT—amiodarone-induced 
thyrotoxicosis).
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are no contraindications to its use) to minimize the manifestations of the overactive 
thyroid. Thyroid tests (TSH, free T4, total T3) should be measured initially at 4- to 
6-week interval and then less frequently (TSH and free T4 every 3 months) depend-
ing upon the results of prior testing. Beta blockers can be tapered and discontinued 
after thyroid tests return to normal.
Due to the lack of sufficient evidence, there is no consensus regarding the 
decision to continue or stop amiodarone in patients with type 1 AIT. The decision 
should be individualized taking into account the risks of patients and taken jointly 
by cardiologists and endocrinologist [40]. Amiodarone should be continued in 
critically ill patients with life-threatening cardiac disorders [88]. When deciding 
whether to discontinue amiodarone, the following should be considered: amioda-
rone may be necessary to control a life-threatening arrhythmia; since the half-life of 
elimination from the body is prolonged, there is no immediate benefit to stopping 
amiodarone; amiodarone appears to ameliorate hyperthyroidism by blocking T4 
to T3 conversion, beta-adrenergic receptors, and possibly T3 receptors. Stopping 
amiodarone might actually exacerbate hyperthyroid symptoms and signs.
In case of amiodarone withdrawal, after the restoration of euthyroidism and nor-
malization of urinary iodine excretion (generally 6–12 months), radioactive iodine 
(RAI) therapy can be performed. Recombinant human TSH (rhTSH) administration 
increases the sensibility of the thyroid gland to RAI therapy. If RAI administration is 
contraindicated, total thyroidectomy should be considered for definitive treatment 
of the underlying thyroid disease [40]. In the absence of the thyroid gland, amioda-
rone reintroduction, when necessary, could be safe. In the case of the thyroid gland is 
conserved, the recurrence rate of type 1 AIT after amiodarone reintroduction is 9% 
[89]. As ETA suggested, emergency thyroidectomy in severe cardiac patients may be 
required not only in type 1 but also in all types of AIT. Prior to thyroid surgery, plas-
mapheresis is able to remove the excess of thyroid hormones [40]. It was reported in 
a study, including seven patients with AIT, that iopanoic acid short-course adminis-
tration prior surgery permitted a safe and uneventful thyroidectomy [90].
Thioamides (thiamazole, carbimazole, propylthiouracil) are effective in older 
patients with underlying heart disease having severe and prolonged (>1 month) 
hyperthyroid symptoms, except the emergency situations. All thioamides are block-
ing thyroid hormones synthesis, propylthiouracil having an additional inhibiting 
effect on T4–T3 transformation. ATA recommended, the starting dose of thiam-
azole, to be 10–20 mg once daily because of its long duration of action, allowing 
for once-daily dosing, more rapid efficacy, and lower incidence of side effects [87]. 
ETA recommended very high daily doses of the drug (40–60 mg/day of thiamazole) 
for a more extended time, considering that in type 1 AIT the iodine-enriched 
thyroid gland of patients is less responsive to thioamides [40]. Carbimazole, the 
prodrug of thiamazole, is an alternative choice of treatment, available in some 
European countries, but not in Romania. Due to the teratogenicity of thiamazole, 
propylthiouracil (not currently available in Romania) can be used in the first 
trimester of pregnancy [68]. To increase the sensitivity and response of the thyroid 
gland to thioamides, potassium or sodium perchlorate (not available in Romania) 
has been used. Perchlorate reduces thyroid iodine uptake by sodium/iodide sym-
porter inhibiting action and discharge iodine from the thyroid, but toxic effects are 
limiting its use. To minimize the nephro- and medullotoxicity of the drug, doses not 
exceeding 4 × 250 mg/day and a shorter period than 4–6 weeks were used [40, 87, 91]. 
Thyroid function should be assessed after 4 weeks by measurement of serum TSH, 
free T4, and T3. The dose of thiamazole is then tapered with the goal of maintain-
ing a euthyroid state. Thereafter, thyroid function tests (TSH, free T4) should be 
measured every 3 months. Many patients with underlying autonomous nodular 
thyroid disease are able to taper and discontinue thiamazole within 6–12 months. In 
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case of thioamide allergy, lithium is used to control the hyperthyroidism temporar-
ily [91, 92], but it has a narrow therapeutic range, produces nephrotoxicity, and its 
efficacy is not well documented. Therefore, it is not recommended by ETA for the 
type 1 AIT treatment [40]. However, it was reported that lithium-associated rhTSH 
administration increases RAI sensibility of the thyroid follicles in AIT [93].
After resolution of the acute episode of iodine-induced hyperthyroidism, 
treatment of the underlying thyroid disease should be addressed. For patients with 
underlying Graves’ disease, treatment options include continuing thiamazole, 
radioiodine ablation, or surgery. Patients with underlying autonomous adenoma or 
multinodular goiter who return to euthyroidism after discontinuation of iodine do 
not necessarily require definitive treatment. However, these patients are at risk for 
recurrent hyperthyroidism if given iodine again.
Type 2 AIT generally is self-limited and amiodarone is not necessary to discon-
tinue. When the efficacy of non-thioamide type antithyroid drugs to restore euthy-
roid state was compared, the best results were obtained with 30 mg oral prednisone 
therapy. The rate of achievement of euthyroid state was 100% when glucocorticoids 
were used versus 71% obtained after perchlorate administration [94]. ETA recom-
mendation, for this reason, is oral glucocorticoids as the first-line treatment for 
type 2 AIT. In patients in whom a mixed form of AIT is suspected, thioamides 
together with glucocorticoids should be given initially, or glucocorticoids should be 
added after a period of 4–6 weeks of inadequate response [40]. In addition, it must 
be noted that i.v. administration of glucocorticoids (hydrocortisone, dexametha-
sone) has crucial benefits (inhibiting T4 transformation to T3) in thyroid storm 
and preoperative management of any type of thyrotoxicosis [91]. It was reported 
that glucocorticoid therapy (oral prednisone) restored the normal thyroid function 
and shrink goiter, preventing surgery, in a patient diagnosed with iodine containing 
supplement-induced hyperthyroidism [95].
5. Conclusions
Iodine, as an essential microelement of the human body, plays a very important 
role in thyroid physiology. Adequate intake is necessary to keep thyroid hormone 
synthesis at normal rate. Dietary intake and urinary excretion should be equivalent, 
but a remarkable adaptive capacity of the thyroid gland can compensate for excess 
intake on short term. However, existing thyroid disease (subclinical or overt) or spe-
cific risk factors may impair the patient’s response to high iodine exposure, which can 
result in hypothyroidism or hyperthyroidism. On the other hand, iodine excess may 
also be hardly recognizable because various sources (e.g. seafood, kelp, dairy prod-
ucts, iodized salt, iodized water, nutritional supplements, iodine containing contrast 
media, and drugs) can all contribute to iodine intake. Of these, iodine containing 
contrast media and drugs are administered only under controlled conditions but 
represent the most frequent cause of iodine-induced thyrotoxicosis. In general, pre-
ventive actions are not recommended, but screening for risk factors, such as elderly 
patients, persons with multinodular goiter, subclinical hyperthyroidism, or manifest 
hyperthyroidism should take place prior to iodine administration. Consequently, 
high-risk patients should benefit preventive treatment with thioamide or perchlorate. 
Amiodarone-induced thyrotoxicosis has remained a difficult task requiring a close 
collaboration between cardiology and endocrinology to overcome complications, but 
individualization of the therapy should be undertaken. Based on the specific features 
of thyrotoxicosis, thioamides, perchlorate, or high-dose glucocorticoids may be 
considered for an optimal therapeutic intervention. If contraindicated, radioiodine 
therapy may also be useful to treat amiodarone-induced thyrotoxicosis.
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